Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands

Bioorganic and Medicinal Chemistry Letters

Volumn 12, Issue 21, 2002, Pages 3077-3079

  Faghih, Ramin ^a   Dwight, Wesley ^a,b   Vasudevan, Anil ^a   Dinges, Jurgen ^a   Conner, Scott E ^a,c   Esbenshade, Timothy A ^a   Bennani, Youssef L ^a,d   Hancock, Arthur A ^a  

^a ABBOTT LABORATORIES   (United States)

^b NEUROCRINE BIOSCIENCES INC   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d ATHERSYS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE; AMINOALKOXYBIPHENYLNITRILE; HISTAMINE H3 RECEPTOR; LIGAND; NITRILE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; NONHUMAN; RAT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIPHENYL COMPOUNDS; CEREBRAL CORTEX; GUINEA PIGS; HUMANS; LIGANDS; NITRILES; RATS; RECEPTORS, HISTAMINE H1; RECEPTORS, HISTAMINE H2; RECEPTORS, HISTAMINE H3; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037020719     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00648-0     Document Type: Article

References (31)

1. (a) Leurs R., Watanabe T., Timmerman H. Trends Pharmacol. Sci. 22:2001;337.
2. (b) Hough B.L. Mol. Pharmacol. 59:2001;415.
3. (a) Ash A.S.F., Schild H.O. Br. J. Pharmacol. 27:1966;427.
4. (b) Kinsolving C.R., Munro N.L., Carr A.A. Pharmacologist. 15:1973;221.
5. Black J.W., Duncan W.A.M., Durant G.J., Ganellin C.R., Parsons E. M. Nature (London). 236:1972;385.
6. (a) Arrang J.-M., Garbarg M., Schwartz J.-C. Nature (London). 302:1983;832.
7. (b) Arrang J.-M., Garbarg M., Lancelot J.-C., Lecomte J.-M., Pollard H., Robba M., Schunack W., Schwartz J.-C. Nature (London). 327:1987;117.
8. 3 Receptor A Target For New drugs, Pharmacochemistry Library, Vol. 30. 1998;Elsevier. Amsterdam
9. (d) Leurs R., Blandina P., Tedford C., Timmerman H. Trends Pharmacol. Sci. 19:1998;177.
10. (e) Lovenberg T.W., Roland B.L., Wilson S.J., Jiang X., Pyati J., Huvar A., Jackson M.R., Erlander M.G. Mol. Pharmacol. 55:1999;1101.
11. (f) Lovenberg T.W., Pyati J., Chang H., Wilson S.J., Erlander M.G. J. Pharmacol. Exp. Ther. 293:2000;771.
12. (g) Leurs R., Hoffmann M., Wieland K., Timmerman H. Trends Pharmacol. Sci. 21:2000;11.
13. (a) Stark H., Schlicker E., Schunack W. Drugs Fut. 21:1996;507
14. (b) Tozer M.J., Kalindjian S.B. Exp. Opin. Ther. Patents. 10:2000;1045.
15. © Halpern M.T. Curr. Opin. Cent. Peripher. Nerv. Syst. Invest. Drugs. 1:1999;524
16. (d) Ali S.M., Tedford C.E., Gregory R., Handley M.K., Yates S.L., Hirth W.W., Phillips J.G. J. Med. Chem. 42:1999;903.
17. (e) Fox G.B., Pan J.B., Esbenshade T.A., Bennani Y.L., Black L.A., Faghih R., Hancock A.A., Decker M.W. Behav. Brain Res. 131:2002;151.
18. Faghih, R.; Dwight, Gentles, R.; Phelan, K.; Esbenshade, T.; Ireland, L.; Miller, T.; Kang, C.-H.; K.; Fox, G.; Gopalakrishnan, S. M.; Hancock, A. A.; Bennani, Y. L. Bioorg. Med. Chem. Lett. In press.
19. Hancock, A. A.; Esbenshade, T. E. In Current Protocols In Pharmacology; Enna, Williams, Ferkany, Kenakin, Porsolt and Sullivan, Eds.; John Wiley & Sons, 2000; Vol. 1.19, pp 1-22.
20. Garbarg M., Arrang J.-M., Rouleau A., Ligneau X., Tuong M.D., Schwartz J.-C., Ganellin C.R. J. Pharmacol. Exp. Ther. 263:1992;304.
21. Weinges K., Spaening R. Chem. Ber. 101:1968;3010.
22. Lovenberg T.W., Roland B.L., Wilson S.J., Jiang X., Pyati J., Huvar A., Jackson M.R., Erlander M.G. Mol. Pharmacol. 55:1999;1101.
23. (a) Tardivel-Lacombe J., Rouleau A., Heron A., Morisset S., Pillot C., Cochois V., Schwartz J.-C., Arrang J.-M. Neuroreport. 11:2000;755.
24. (b) Drutel G., Peitsaro N., Karlstedt K., Wieland K., Smit M.J., Timmerman H., Panula P., Leurs R. Mol. Pharmacol. 59:2000;1.
25. Ligneau X., Morisset S., Tardivel-Lacombe J., Gbahou F., Ganellin C.R., Stark H., Schunack W., Schwartz J.-C., Arrang J.-M. Brit. J. Pharmacol. 131:2000;1247.
26. (a) Denny L.I., Parihar A.S., Miller T.R., Kang C.H., Bennani Y.L., Krueger K.M., Esbenshade T.A., Hancock A.A. Eur. J. Pharmacol. 433:2001;141.
27. (b) Lovenberg T.W., Pyati J., Chang H., Wilson S.J., Erlander M.G. J. Pharmacol. Exp. Ther. 293:2000;771.
28. © Ligneau X., Morisset S., Tardivel-Lacombe J., Gbahou F., Ganellin C.R., Stark H., Schunack W., Schwartz J.-C., Arrang J.-M. Brit. J. Pharmacol. 131:2000;1247.
29. (a) Bush E.N., Shapiro R., Nuss M., Knourek-Segel V., Wilcox D., Droz B., Faghih R., Bennani Y., Esbenshade T., Jacobson P.B., Hancock A.A. Abstracts, American Diabetes Association. 2002.
30. (b) Krueger K.M., Kang C.H., Miller T., Witte D., Faghih R., Bennani Y., Esbenshade T.A., Hancock A. Pharmacologist. 44 (Suppl 1):2002;A196.
31. © Hancock A., Fox G., Bush E., Shapiro R., Nuss M., Knourek-Segel V., Wilcox D., Droz B., Jacobson P., Bennani Y., Esbenshade T., Faghih R. Pharmacologist. 44(Suppl 1):2002;A157.